Skip to content
2000
Volume 16, Issue 4
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Machine Learning, a fast-growing technology, is an application of Artificial Intelligence that has provided important contributes to drug discovery and clinical development. In the last few years, the number of clinical applications based on Machine Learning has been constantly growing and this is now affecting the National Competent Authorities during the assessment of most recently submitted Clinical Trials that are designed, managed or that are generating data deriving from the use of Machine Learning or Artificial Intelligence technologies. We review current information available on the regulatory approach to Clinical Trials and Machine Learning. We also provide inputs for further reasoning and potential indications, including six actionable proposals for regulators to proactively drive the upcoming evolution of Clinical Trials within a strong regulatory framework, focusing on patient’s safety, health protection and fostering immediate access to effective treatments.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/1574887116666210715114203
2021-11-01
2025-09-12
Loading full text...

Full text loading...

/content/journals/rrct/10.2174/1574887116666210715114203
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test